According to the new market research report "Digital PCR Market by Product (Instruments, Reagents & Consumables, Software & Services), Application (Clinical, Research, Forensic), End User (Hospitals & Diagnostic Centers, Pharma Biotech, CROs) - Global Forecast to 2025", published by MarketsandMarkets™, the dPCR and qPCR market is projected to reach USD 7.6 billion by 2025 from USD 4.9 billion in 2020, at a CAGR of 9.0% between 2020 and 2025.
Browse in-depth TOC on "Digital PCR Market"
253 – Tables
41 – Figures
316 – Pages
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=174151204
The Factors such as the rising incidence of target infectious diseases and genetic disorders; technological advancements in PCR technologies; increasing investments, funds, and grants; increasing use of biomarker profiling for disease diagnostics; and successful completion of the Human Genome Project are driving the growth of this market. However, the high instrument costs—especially that of dPCR—and the technical limitations of PCR have restricted their greater use.
qPCR reagents and consumables accounted for the largest share of qPCR market
Based on products & services, the market is categorized into reagents and consumables, instruments and software & services. The qPCR reagents and consumables segment is expected to command the largest share of the qPCR products & services market in 2020, owing to the factors such as the expanding applications of qPCR (owing to its technological benefits over traditional PCR, such as real-time analysis and reduced analysis time), growing private-public funding for life science research, and the rising number of probe-based multiplex genetic analysis procedures (that require the analysis of low-volume gene samples).
Clinical application segment accounted for the largest share of qPCR market
Based on application, the market is categorized into clinical applications (Infectious Disease Testing, Oncology Testing, Blood Screening, Transplant Diagnostics and Other Clinical Applications), research applications and forensic applications. The clinical applications segment is estimated to dominate the qPCR applications market in 2020. The key factors driving the market growth of cclinical applications segment include the growing usage of qPCR in disease diagnosis, rising incidence of infectious and genetic diseases, and growing public emphasis on early & effective disease diagnosis & treatment.
The hospitals and diagnostic centers is the largest and fastest gowing end user segment of the qPCR market
Based on end users, the Digital PCR Market is segmented into research laboratories and academic institutes, pharmaceutical and biotechnology companies, hospitals and diagnostic centers, clinical research organizations (CROs), and forensic laboratories. In 2019, the hospitals and diagnostic centers segment accounted for the largest share of the market. This can be attributed to the increasing market availability of qPCR reagents for clinical diagnostic applications, ongoing expansion of healthcare infrastructure across emerging countries, high prevalence of target diseases, and growing awareness among end users related to the benefits offered by qPCR for clinical diagnosis.
North America accounted for the largest share of the dPCR market
North America accounted for the largest share of the Digital PCR Market, followed by Europe in 2019. The large share of the North American regional segment can be attributed to the increased adoption of innovative and novel genomic analysis products (including advanced qPCR and dPCR products), availability of R&D funding for genomic research (coupled with the robust research infrastructure in the region), expanding use of PCR techniques in clinical diagnostics & forensics, and early commercialization of qPCR/dPCR products compared to other regions.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=174151204
The prominent players operating in the dPCR and qPCR market are Thermo Fisher Scientific (US), Bio-Rad Laboratories Inc. (US), and F. Hoffmann-La Roche, Ltd. (Switzerland).
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Content Source: https://www.marketsandmarkets.com/PressReleases/digital-pcr.asp
Digital PCR is a highly precise approach to sensitive nucleic acid detection and quantification.
The qPCR technology segment is expected to account for the larger share of the global dPCR and qPCR market in 2017; whereas, the dPCR segment is expected to grow at the highest CAGR during the forecast period.
Factors such as ongoing technological developments in dPCR continued expansion in distribution networks of emerging dPCR product manufacturers in global markets, and growing private funding to develop and commercialize innovative dPCR instruments are contributing to the growth of the PCR technology segment.On the basis of application, the PCR and qPCR market is categorized into clinical applications, research applications, and others.
The clinical applications segment is further divided into pathogen testing, oncology testing, blood screening, and other clinical applications.
Through retailer and resells, their authorized distributors or their partners, those Digital PCR (DPCR) and QPCR manufacturers keep keen on expanding their Digital PCR (DPCR) and QPCR sales.
To achieve better sales businesses, Digital PCR (DPCR) and QPCR manufacturers usually invest on their marketing channel infrastructure every year.
Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030: DelveInsight (Albany, US) DelveInsight has introduced a new Market Insights, Epidemiology, and Market Forecast Report on "Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2030" to its portfolio.Key Highlights from report are:As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017.
These cases are expected to grow with a significant CAGR in the study period 2017–2030.There are different types of treatment available for NSCLC; however, mainly 10 types of standard treatment are used, which include Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and Watchful waiting.The market size of NSCLC in the 7MM is expected to increase during study period.
According to the estimates, the highest contribution in the market size of NSCLC is from the United States followed by Japan, Germany, and the UK.One of the most exciting developments in lung cancer medicine is the introduction of targeted treatments.Request for free sample pages to know more on Non-Small Cell Lung Cancer Market Forecast NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers.
The disease epidemiology included in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology, which is segmented as Total Incident cases of NSCLC patients, Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total NSCLC cases of patients by Genetic mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC in the 7MM.The total NSCLC incident cases in the 7MM were observed to be 484,726 cases in 2017.Click here to know more on Non-Small Cell Lung Cancer pipelineNSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.Drugs covered in the report are:-There are several key players robustly involved in developing potential products such asNazartinib (EGF816)Capmatinib (INC280)Tepmetko (tepotinib)MerestinibJNJ-61186372 (JNJ-6372)Vemurafenib Plus CobimetinibX-396 (Ensartinib)Tedopi (OSE2101)Selpercatinib (LY3527723/ LOXO-292)SAR408701Braftovi (encorafinib) + Mektovi (binimetinib)PADCEV (enfortumab vedotin/ASG-22ME)Pralsetinib (BLU-667)TAK-788: Canakinumab (ACZ885)Avelumab (Bavencio)Veliparib (ABT-888): Sitravatinib (MGCD516)TesevatinibRomiplostim: CabozantinibSym015AMG 510INCMGA00012 (MGA012)Libtayo (Cemiplimab)BavituximabM7824 (Bintrafusp alfa)And many others Key Players covered in the report are:-Novartis PharmaceuticalsMerck KGaAEli Lilly and CompanyJanssen Research & DevelopmentHoffmann-La RocheXcoveryBeyondSpring PharmaceuticalsOSE ImmunotherapeuticsSanofiPfizerAstellas PharmaSeattle GeneticsBlueprint Medicines CorporationTakedaAbbVieKadmon CorporationAmgenSymphogenRegeneron PharmaceuticalsPeregrine PharmaceuticalsAvid BioservicesGlaxoSmithKlineAnd many othersThe report includes provides in depth analysis historical and forecasted Market Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by Mutations/Biomarkers, Total Market Size of PD-L1 NSCLC, Total Market Size of BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total Market Size of ALK as well.The reasons for buying this report:The report proffers an overview of pathophysiology, various diagnostic approaches and NSCLC treatment algorithm, including detailed chapters for marketed products and emerging therapies.Historical and forecasted Non-Small Cell Lung Cancer epidemiology in 7MM covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017-2030.Detailed historical and forecasted NSCLC market covering the United States, EU5 and Japan from 2017-2030.
Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with comprehensive clinical profiles, key cross-competition, launch date along with product development activities.
Understand the various factors that will impact the market growth during the forecast period.
Also, learn about challenges faced by key players and opportunities they can leverage to grow in this market.
